Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 13 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.61 Insider Own20.86% Shs Outstand135.04M Perf Week-16.73%
Market Cap107.59M Forward P/E- EPS next Y-0.69 Insider Trans-0.14% Shs Float119.86M Perf Month-20.71%
Income-82.68M PEG- EPS next Q-0.28 Inst Own41.44% Short Float18.85% Perf Quarter-6.65%
Sales126.85M P/S0.85 EPS this Y-6.59% Inst Trans12.80% Short Ratio4.65 Perf Half Y-26.25%
Book/sh-0.39 P/B- EPS next Y27.16% ROA-27.04% Short Interest22.60M Perf Year-88.52%
Cash/sh0.73 P/C0.97 EPS next 5Y- ROE-538.57% 52W Range0.54 - 6.26 Perf YTD-49.26%
Dividend Est.- P/FCF- EPS past 5Y18.22% ROI-56.78% 52W High-88.65% Beta1.98
Dividend TTM- Quick Ratio1.25 Sales past 5Y386.36% Gross Margin89.59% 52W Low31.56% ATR (14)0.13
Dividend Ex-Date- Current Ratio1.68 EPS Y/Y TTM73.88% Oper. Margin-61.09% RSI (14)41.22 Volatility24.86% 14.11%
Employees233 Debt/Eq- Sales Y/Y TTM2380.87% Profit Margin-65.18% Recom2.43 Target Price3.31
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q51.42% Payout- Rel Volume0.34 Prev Close0.75
Sales Surprise-100.00% EPS Surprise20.98% Sales Q/Q100.00% EarningsMay 08 BMO Avg Volume4.86M Price0.71
SMA20-22.30% SMA50-17.23% SMA200-46.20% Trades Volume1,667,585 Change-4.72%
Date Action Analyst Rating Change Price Target Change
Jun-26-23Resumed Oppenheimer Outperform $12
Apr-21-23Initiated JP Morgan Neutral $7
Jul-23-21Downgrade Goldman Neutral → Sell $24 → $7
May-18-21Resumed Goldman Neutral $24
Mar-05-21Upgrade Chardan Capital Markets Neutral → Buy $30
Sep-18-20Downgrade Chardan Capital Markets Buy → Neutral $32.50 → $27.50
Aug-18-20Initiated Piper Sandler Overweight $40
Aug-11-20Upgrade Jefferies Hold → Buy $4 → $29
Aug-11-20Reiterated H.C. Wainwright Buy $8 → $41
Apr-30-19Initiated Jefferies Hold $7
Jun-12-24 07:00AM
Jun-07-24 04:00PM
Jun-06-24 07:05AM
06:30AM Loading…
May-13-24 12:18PM
May-09-24 11:06AM
May-08-24 11:54AM
04:01PM Loading…
May-06-24 04:01PM
Apr-09-24 07:00AM
Apr-08-24 08:00AM
Mar-28-24 07:00AM
Mar-19-24 08:30AM
Mar-13-24 03:32PM
Mar-07-24 11:48AM
Mar-06-24 02:17AM
Mar-05-24 09:51AM
Feb-28-24 07:00AM
07:00AM Loading…
Feb-27-24 07:00AM
Feb-26-24 07:00AM
Jan-17-24 07:00AM
Jan-09-24 08:44AM
Jan-08-24 06:30AM
Jan-04-24 04:00PM
Dec-07-23 07:46PM
Nov-28-23 09:18AM
Nov-27-23 07:01PM
Nov-21-23 06:00AM
Nov-05-23 02:22PM
Nov-02-23 08:47AM
Nov-01-23 10:30AM
Oct-30-23 05:30PM
Oct-19-23 10:30AM
Oct-12-23 07:00AM
Oct-06-23 07:00AM
Oct-02-23 07:00AM
Sep-27-23 08:31AM
Sep-11-23 06:30AM
Sep-08-23 07:00AM
Sep-07-23 10:00AM
Aug-29-23 09:00AM
Aug-09-23 06:27AM
Aug-08-23 08:25AM
Aug-04-23 07:00AM
Aug-01-23 07:00AM
Jul-14-23 04:01PM
Jul-07-23 10:17AM
Jun-21-23 09:00AM
Jun-17-23 03:45PM
Jun-09-23 07:00AM
Jun-05-23 07:00AM
Jun-02-23 07:00AM
May-30-23 04:00PM
May-16-23 06:00AM
May-10-23 07:00AM
May-09-23 08:15AM
May-08-23 07:00AM
May-05-23 07:00AM
Apr-29-23 09:03AM
Apr-27-23 10:03AM
Apr-26-23 07:46PM
Apr-24-23 02:09AM
Apr-20-23 09:45AM
Apr-14-23 05:10AM
Apr-07-23 07:00AM
Apr-04-23 04:30PM
Mar-22-23 03:44AM
Mar-09-23 07:00AM
Mar-08-23 10:45PM
Mar-07-23 10:28PM
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shaff Eric D.CEO and PresidentMay 15 '24Sale0.942,4352,289140,698May 17 08:18 PM
Ege David S.See RemarksMay 15 '24Sale0.941,0901,02575,734May 17 08:16 PM
von Moltke LisaSee RemarksMay 15 '24Sale0.9493988319,017May 17 08:23 PM
Henn Matthew R.See RemarksMay 15 '24Sale0.9489183865,357May 17 08:17 PM
DesRosier ThomasChief Legal Officer and EVPMay 15 '24Sale0.94843792122,390May 17 08:14 PM
Young Teresa L.See RemarksMay 15 '24Sale0.9470366117,658May 17 08:18 PM
Shaff Eric D.CEO and PresidentFeb 16 '24Sale1.0811,54912,473135,321Feb 16 09:42 PM
Ege David S.See RemarksFeb 16 '24Sale1.085,0105,41173,856Feb 16 09:15 PM
von Moltke LisaSee RemarksFeb 16 '24Sale1.084,4004,75216,988Feb 16 09:21 PM
Henn Matthew R.See RemarksFeb 16 '24Sale1.084,1704,50463,436Feb 16 09:31 PM
Arkowitz DavidChief Financial OfficerFeb 16 '24Sale1.083,9394,254182,442Feb 16 09:13 PM
DesRosier ThomasChief Legal Officer and EVPFeb 16 '24Sale1.083,9394,254120,577Feb 16 09:48 PM
Young Teresa L.See RemarksFeb 16 '24Sale1.083,3743,64415,705Feb 16 09:29 PM
Shaff Eric D.CEO and PresidentOct 30 '23Sale1.358,55211,545115,620Oct 31 09:40 PM
von Moltke LisaSee RemarksOct 30 '23Sale1.354,2325,7139,513Oct 31 09:36 PM
DesRosier ThomasChief Legal Officer and EVPOct 30 '23Sale1.354,1565,611113,891Oct 31 09:39 PM
Arkowitz DavidChief Financial OfficerOct 30 '23Sale1.354,0665,489175,756Oct 31 09:39 PM
Ege David S.See RemarksOct 30 '23Sale1.354,0665,48966,991Oct 31 09:39 PM
Henn Matthew R.See RemarksOct 30 '23Sale1.353,8865,24656,356Oct 31 09:36 PM
Young Teresa L.See RemarksOct 30 '23Sale1.352,9073,9248,454Oct 31 09:40 PM
Cloghessy PaulaSee RemarksOct 30 '23Sale1.352,9043,92045,684Oct 31 09:43 PM
Young Teresa L.See RemarksOct 27 '23Option Exercise0.0011,361011,361Oct 31 09:40 PM
Cloghessy PaulaSee RemarksOct 27 '23Option Exercise0.009,418048,588Oct 31 09:43 PM
Shaff Eric D.CEO and PresidentOct 27 '23Option Exercise0.0027,8380124,172Oct 31 09:40 PM
Arkowitz DavidChief Financial OfficerOct 27 '23Option Exercise0.0013,2090179,822Oct 31 09:39 PM
Ege David S.See RemarksOct 27 '23Option Exercise0.0011,361071,057Oct 31 09:39 PM
DesRosier ThomasChief Legal Officer and EVPOct 27 '23Option Exercise0.0013,5010118,047Oct 31 09:39 PM
Henn Matthew R.See RemarksOct 27 '23Option Exercise0.0012,623060,242Oct 31 09:36 PM
von Moltke LisaSee RemarksOct 27 '23Option Exercise0.0013,745013,745Oct 31 09:36 PM